Adaptin Bio (APTN) Amortization of Deferred Charges (2024 - 2025)
Adaptin Bio's (APTN) quarterly Amortization of Deferred Charges came in at $53722.0 in Q1 2025, up 101.46% year-over-year from $26666.0 in Q1 2024, and down 50.44% quarter-over-quarter from $108389.0 in Q4 2024.
Powered by 
Analysis
Adaptin Bio (APTN) Amortization of Deferred Charges (2024 - 2025) Analysis & Trends
Adaptin Bio has disclosed Amortization of Deferred Charges across 2 years of filings, most recently posting $53722.0 for Q1 2025.
- In Q1 2025, Amortization of Deferred Charges rose 101.46% year-over-year to $53722.0; the TTM figure through Dec 2025 stood at $53722.0 (down 77.6% YoY), while the FY2025 annual figure was $53722.0, down 77.6% from the prior year.
- Amortization of Deferred Charges came in at $53722.0 for Q1 2025 at Adaptin Bio, down from $108389.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $108389.0 in Q4 2024 to a low of $22881.0 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn |
| 10 | Adaptin Bio | 56.76 Mn | 56.09 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 53,722.00 |
| Dec 31, 2024 | 108,389.00 |
| Sep 30, 2024 | 81,853.00 |
| Jun 30, 2024 | 22,881.00 |
| Mar 31, 2024 | 26,666.00 |